Additional information
| Active substance | Bortezomib |
|---|---|
| Formula | C19H25BN4O4 |
| Side effects | Peripheral neuropathy, fatigue, gastrointestinal disturbances, thrombocytopenia, neutropenia, anemia, pyrexia |
| Effects | Induces apoptosis and inhibits cell growth and proliferation |
| Dosage (sports) | Not applicable |
| Dosage (medical) | Typically 1.3 mg/m^2 body surface area, administered as an intravenous injection twice a week for two weeks, followed by a 10-day rest period |
| Half-life | 9 to 15 hours |
| Main action | Inhibits the 26S proteasome |
| Substance class | Proteasome inhibitor |
| Chemical name | [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid |
| Storage conditions | Store at 2В°C to 8В°C (36В°F to 46В°F) in original package to protect from light |
| Trade name | Velcade |
| Blood pressure | Can cause hypotension or hypertension |
| WAREHOUSE | International Warehouse 2 |
| Also known as | PS-341 |
| Lab Test | Blood counts, liver enzymes, and renal function tests should be monitored |
| Hepatotoxicity | Low |
| Water Retention | Minimal |
| Use in sports | None |
| Manufacturer | Janssen-Cilag |
Reviews
There are no reviews yet.